Company / R&D per Share
Janux Therapeutics, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.03
FY2025
5-year range
$1.12 / $2.03
FY2021-FY2025
Trend
+59.7%
vs FY2024
Sector context
#101 of 207
Health Care
What the data says
At $2.03, Janux Therapeutics, Inc.'s r&d per share ranks #101 of 207 in the Health Care sector. R&D per Share has fluctuated over the past 6 years, ranging from $1.12 in FY2021 to $3.32 in FY2020.
Based on SEC 10-K filings.
2.03 in FY2025 with a 5-year CAGR of -9.4%.
Improved from $1.25 to $2.03 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- -9.4%
- 10-Year CAGR
- -
Sector benchmark
#101 of 207 in Health CareTop 49% of 207This company $2.03 Sector average $12.26
▼
-83.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 59.7% year-over-year.
- Ranks #101 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.03 | +59.7% |
| FY2024 | $1.27 | +2.0% |
| FY2023 | $1.25 | -3.2% |
| FY2022 | $1.29 | +15.6% |
| FY2021 | $1.12 | -66.4% |
| FY2020 | $3.32 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026